1
|
Jiang SL, Li L, Kou SB, Hu L, Shi JH. Insight into intermolecular binding mechanism of apatinib mesylate and human alpha-1-acid glycoprotein: combined multi-spectroscopic approaches with in silico. J Biomol Struct Dyn 2024; 42:779-790. [PMID: 37000929 DOI: 10.1080/07391102.2023.2195015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Accepted: 03/19/2023] [Indexed: 04/03/2023]
Abstract
Apatinib mesylate (APM), an oral tyrosine kinase inhibitor, has a good anti-tumor activity in the treatment of various cancers, particularly in advanced non-small cell lung cancer. In this study, the intermolecular binding mechanism between APM and human alpha-1-acid glycoprotein (HAG) was investigated by combining multi-spectroscopic approaches with in silico techniques. The findings revealed that APM gave rise to the fluorescence quenching of HAG by forming a ground-state complex between APM and HAG with a stoichiometric ratio of 1:1, and APM has a moderate affinity for HAG as the binding constant of APM and HAG of approximately 105 M-1, which was larger than the APM-HAG complex. The findings from thermodynamic parameter analysis indicated that the dominant driving forces for the formation of the APM-HAG complex were van der Waals forces, hydrogen bonding and hydrophobic interactions, which were also verified with site-probe studies and molecular docking. The findings from in silico study indicated that APM inserted into the opening of the hydrophobic cavity of HAG, leads to a slight conformational change in the HAG, which was verified by circular dichroism (CD) measurements, that was, the beta sheet level of HAG decreased. Additionally, the results of synchronous and 3D fluorescence spectroscopies confirmed the decline in hydrophobicity of the microenvironment around Trp and Tyr residues. Moreover, some common metal ions such as Cu2+, Mg2+, Fe3+, Ca2+, and Zn2+ could cause the alteration in the binding constant of APM with HAG, leading to the change in the efficacy of APM. It will be expected that these study findings are to provide useful information for further understanding pharmacokinetic and structural modifications of APM.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Shao-Liang Jiang
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou, China
| | - Li Li
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou, China
| | - Song-Bo Kou
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou, China
| | - Lu Hu
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou, China
| | - Jie-Hua Shi
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou, China
| |
Collapse
|
2
|
Li Z, Chen R, Qin C, Lu P, Lin J, Zheng W, Xiong Y, Li C. Assessment of the Binding of Pseudallecin A to Human Serum Albumin with Multi-Spectroscopic Analysis, Molecular Docking and Molecular Dynamic Simulation. Chem Biodivers 2023; 20:e202301217. [PMID: 37870539 DOI: 10.1002/cbdv.202301217] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2023] [Revised: 10/17/2023] [Accepted: 10/22/2023] [Indexed: 10/24/2023]
Abstract
The binding of pseudallecin A (PA), a potential antibiotic with strong inhibitory activities against Gram-positive Escherichia coli and Gram-negative Staphylococcus aureus, to human serum albumin (HSA) was explored. The interaction between them was assessed by multi-spectroscopic analysis, binding site competitive analysis, molecular docking and molecular dynamic simulation, showing the results as follows: PA effectively quenched the innate fluorescence of HSA by a static quenching process, formed a complex at a molar ratio of approximately 1 : 1 and performed an effective non-radiative energy transfer; the binding of PA to HSA was a spontaneous exothermic reaction driven by enthalpy with strong affinity and had a slight effect on the conformation of HSA; PA bound at site III of HSA and hydrogen bonds were the major binding forces to maintain the stability of the PA-HSA complex. Molecular dynamic simulation was performed to calculate the root mean square deviation (RMSD), root mean square fluctuation (RMSF) and radius of gyration (Rg) for this complex and effectively supported the spectroscopic outcome. These results meant that the delivery and distribution of PA as a water-insoluble molecule can be efficiently accomplished via HSA in human blood and, it has a good potential for future drug application and pharmacological development.
Collapse
Affiliation(s)
- Ziyang Li
- Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, 510642, Guangzhou, China
| | - Ruolan Chen
- Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, 510642, Guangzhou, China
| | - Chan Qin
- Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, 510642, Guangzhou, China
| | - Peijun Lu
- Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, 510642, Guangzhou, China
| | - Jiaru Lin
- Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, 510642, Guangzhou, China
| | - Wenxu Zheng
- Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, 510642, Guangzhou, China
| | - Yahong Xiong
- Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, 510642, Guangzhou, China
| | - Chunyuan Li
- Key Laboratory for Biobased Materials and Energy of Ministry of Education, College of Materials and Energy, South China Agricultural University, 510642, Guangzhou, China
| |
Collapse
|
3
|
Jiang SL, Hu ZY, Wang WJ, Hu L, Li L, Kou SB, Shi JH. Investigation on the binding behavior of human α1-acid glycoprotein with Janus Kinase inhibitor baricitinib: Multi-spectroscopic and molecular simulation methodologies. Int J Biol Macromol 2023:125096. [PMID: 37285878 DOI: 10.1016/j.ijbiomac.2023.125096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2023] [Revised: 05/22/2023] [Accepted: 05/23/2023] [Indexed: 06/09/2023]
Abstract
Baricitinib is a Janus Kinase (JAK) inhibitor that is primarily used to treat moderately to severely active rheumatoid arthritis in adults and has recently been reported for the treatment of patients with severe COVID-19. This paper describes the investigation of the binding behavior of baricitinib to human α1-acid glycoprotein (HAG) employing a variety of spectroscopic techniques, molecular docking and dynamics simulations. Baricitinib can quench the fluorescence from amino acids in HAG through a mix of dynamic and static quenching, according to steady-state fluorescence and UV spectra observations, but it is mainly static quenching at low concentration. The binding constant (Kb) of baricitinib to HAG at 298 K was at the level of 104 M-1, indicating a moderate affinity of baricitinib to HAG. Hydrogen bonding and hydrophobic interactions conducted the main effect, according to thermodynamic characteristics, competition studies between ANS and sucrose, and molecular dynamics simulations. For the change in HAG conformation, the results of multiple spectra showed that baricitinib was able to alter the secondary structure of HAG as well as increase the polarity of the microenvironment around the Trp amino acid. Furthermore, the binding behavior of baricitinib to HAG was investigated by molecular docking and molecular dynamics simulations, which validated experimental results. Also explored is the influence of K+, Co2+, Ni2+, Ca2+, Fe3+, Zn2+, Mg2+ and Cu2+plasma on binding affinity.
Collapse
Affiliation(s)
- Shao-Liang Jiang
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou 310032, China.
| | - Zhe-Ying Hu
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou 310032, China
| | - Wan-Jun Wang
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou 310032, China
| | - Lu Hu
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou 310032, China
| | - Li Li
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou 310032, China
| | - Song-Bo Kou
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou 310032, China
| | - Jie-Hua Shi
- College of Pharmaceutic Science, Zhejiang University of Technology, Hangzhou 310032, China.
| |
Collapse
|
4
|
Exploring binding interaction of baricitinib with bovine serum albumin (BSA): multi-spectroscopic approaches combined with theoretical calculation. J Mol Liq 2022. [DOI: 10.1016/j.molliq.2022.118831] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
5
|
Saber Abdelhameed A, Bakheit AH, Hassan ES, Alanazi AM, Naglah AM, AlRabiah H. Spectroscopic and computational investigation of the interaction between the new anticancer agent enasidenib and human serum albumin. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2022; 270:120790. [PMID: 34974294 DOI: 10.1016/j.saa.2021.120790] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Revised: 12/16/2021] [Accepted: 12/18/2021] [Indexed: 06/14/2023]
Abstract
Enasidenib (EDB) is a new therapeutic agent for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. This research aimed at utilizing experimental and theoretical approaches to characterize the binding mechanism between EDB and human serum albumin (HSA). Formation of an EDB-HSA static complex was demonstrated by quenching of the HSA intrinsic fluorescence by EDB. Using well known mathematical relations (e.g. Stern-Volmer and Lineweaver-Burk equations), the recorded EDB-HSA fluorescence data were interpreted and revealed binding constants in the magnitude order of 104 M-1 for the different investigated temperatures. These determined results were taken into further mathematical calculations to reveal the thermodynamic properties of EDB-HSA binding. Results demonstrated that spontaneous EDB and HSA binding takes place led by electrostatic forces. Computational docking studies have further confirmed the latter finding showing that EDB fits into the HSA Sudlow site I. Molecular dynamic simulation was performed to calculate the root mean square deviation (RMSD), root mean square fluctuation (RMSF), radius of gyration (Rg) and hydrogen bond parameters for the EDB-HSA complex.
Collapse
Affiliation(s)
- Ali Saber Abdelhameed
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
| | - Ahmed H Bakheit
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
| | - Eman S Hassan
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
| | - Amer M Alanazi
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
| | - Ahmed M Naglah
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia
| | - Haitham AlRabiah
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
| |
Collapse
|
6
|
Liu J, Chen J, Liu X, Shao W, Mei X, Tang Z, Cao X. Binding mechanism of lipase with Lentinus edodes mycelia polysaccharide by multi-spectroscopic methods. J Mol Recognit 2021; 35:e2946. [PMID: 34918387 DOI: 10.1002/jmr.2946] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 11/16/2021] [Accepted: 12/05/2021] [Indexed: 11/12/2022]
Abstract
It is an effective strategy to avoid obesity by inhibiting the activity of lipase. In this study, the binding mechanism of lipase and Lentinus edodes mycelia polysaccharide (LMP) were explored with multi-spectral methods, for example, three-dimensional (3D) fluorescence, Fourier-transformed infrared (FT-IR), and Raman spectra. At 290 K, the binding constant was 2.44 × 105 L/mol, there was only one binding site between LMP and lipase. Static quenching was the quenching mechanism. The major forces were hydrogen bonding and van der Waals force. The binding of LMP to lipase impacted the microenvironment around tyrosine and tryptophan residues. The polarity around these residues was decreased and hydrophobicity was enhanced. This study not only revealed the binding mechanism of LMP on lipase but also provided scientific evidence for expanding the application of LMP in functional food industries.
Collapse
Affiliation(s)
- Jianli Liu
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, China
| | - Jiahe Chen
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, China
| | - Xiangyang Liu
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, China
| | - Wei Shao
- Biology Subject teaching, College of Life Science and Technology, Mudanjiang Normal University, Mudanjiang, China
| | - Xueying Mei
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, China
| | - Zhipeng Tang
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, China
| | - Xiangyu Cao
- Department of Biological Sciences, School of life Science, Liaoning University, Shenyang, China
| |
Collapse
|
7
|
Tullemans BM, Karel MF, Léopold V, ten Brink MS, Baaten CC, Maas SL, de Vos AF, Eble JA, Nijziel MR, van der Vorst EP, Cosemans JM, Heemskerk JW, Claushuis TA, Kuijpers MJ. Comparison of inhibitory effects of irreversible and reversible Btk inhibitors on platelet function. EJHAEM 2021; 2:685-699. [PMID: 35845214 PMCID: PMC9175945 DOI: 10.1002/jha2.269] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 07/13/2021] [Accepted: 07/13/2021] [Indexed: 12/11/2022]
Abstract
All irreversible Bruton tyrosine kinase (Btk) inhibitors including ibrutinib and acalabrutinib induce platelet dysfunction and increased bleeding risk. New reversible Btk inhibitors were developed, like MK-1026. The mechanism underlying increased bleeding tendency with Btk inhibitors remains unclear. We investigated the effects of ibrutinib, acalabrutinib and MK-1026 on platelet function in healthy volunteers, patients and Btk-deficient mice, together with off-target effects on tyrosine kinase phosphorylation. All inhibitors suppressed GPVI- and CLEC-2-mediated platelet aggregation, activation and secretion in a dose-dependent manner. Only ibrutinib inhibited thrombus formation on vWF-co-coated surfaces, while on collagen this was not affected. In blood from Btk-deficient mice, collagen-induced thrombus formation under flow was reduced, but preincubation with either inhibitor was without additional effects. MK-1026 showed less off-target effects upon GPVI-induced TK phosphorylation as compared to ibrutinib and acalabrutinib. In ibrutinib-treated patients, GPVI-stimulated platelet activation, and adhesion on vWF-co-coated surfaces were inhibited, while CLEC-2 stimulation induced variable responses. The dual inhibition of GPVI and CLEC-2 signalling by Btk inhibitors might account for the increased bleeding tendency, with ibrutinib causing more high-grade bleedings due to additional inhibition of platelet-vWF interaction. As MK-1026 showed less off-target effects and only affected activation of isolated platelets, it might be promising for future treatment.
Collapse
Affiliation(s)
- Bibian M.E. Tullemans
- Department of BiochemistryCardiovascular Research Institute MaastrichtMaastricht UniversityMaastrichtThe Netherlands
| | - Mieke F.A. Karel
- Department of BiochemistryCardiovascular Research Institute MaastrichtMaastricht UniversityMaastrichtThe Netherlands
| | - Valentine Léopold
- Center for Experimental and Molecular MedicineAmsterdam University Medical Centres, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands
- Hopital LariboisiereDepartment of Anaesthesiology and Critical CareParisFrance
| | - Marieke S. ten Brink
- Center for Experimental and Molecular MedicineAmsterdam University Medical Centres, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands
| | - Constance C.F.M.J. Baaten
- Department of BiochemistryCardiovascular Research Institute MaastrichtMaastricht UniversityMaastrichtThe Netherlands
- Institute for Molecular Cardiovascular Research (IMCAR)University Hospital AachenAachenGermany
| | - Sanne L. Maas
- Institute for Molecular Cardiovascular Research (IMCAR)University Hospital AachenAachenGermany
- Interdisciplinary Center for Clinical Research (IZKF)RWTH Aachen UniversityAachenGermany
| | - Alex F. de Vos
- Center for Experimental and Molecular MedicineAmsterdam University Medical Centres, Academic Medical CentreUniversity of AmsterdamAmsterdamThe Netherlands
| | - Johannes A. Eble
- Institute of Physiological Chemistry and PathobiochemistryUniversity of MünsterMünsterGermany
| | - Marten R. Nijziel
- Department of HaematologyCatharina Hospital EindhovenEindhovenThe Netherlands
| | - Emiel P.C. van der Vorst
- Institute for Molecular Cardiovascular Research (IMCAR)University Hospital AachenAachenGermany
- Interdisciplinary Center for Clinical Research (IZKF)RWTH Aachen UniversityAachenGermany
- Department of PathologyCardiovascular Research Institute Maastricht (CARIM)Maastricht University Medical CentreMaastrichtNetherlands
- Institute for Cardiovascular Prevention (IPEK)Ludwig‐Maximilians‐University MunichMunichGermany
| | - Judith M.E.M. Cosemans
- Department of BiochemistryCardiovascular Research Institute MaastrichtMaastricht UniversityMaastrichtThe Netherlands
| | - Johan W.M. Heemskerk
- Department of BiochemistryCardiovascular Research Institute MaastrichtMaastricht UniversityMaastrichtThe Netherlands
| | | | - Marijke J.E. Kuijpers
- Department of BiochemistryCardiovascular Research Institute MaastrichtMaastricht UniversityMaastrichtThe Netherlands
- Thrombosis Expertise Centre, Heart and Vascular CentreMaastricht University Medical CentreMaastrichtThe Netherlands
| |
Collapse
|
8
|
Sabe VT, Ntombela T, Jhamba LA, Maguire GEM, Govender T, Naicker T, Kruger HG. Current trends in computer aided drug design and a highlight of drugs discovered via computational techniques: A review. Eur J Med Chem 2021; 224:113705. [PMID: 34303871 DOI: 10.1016/j.ejmech.2021.113705] [Citation(s) in RCA: 165] [Impact Index Per Article: 55.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2021] [Revised: 07/12/2021] [Accepted: 07/12/2021] [Indexed: 12/30/2022]
Abstract
Computer-aided drug design (CADD) is one of the pivotal approaches to contemporary pre-clinical drug discovery, and various computational techniques and software programs are typically used in combination, in a bid to achieve the desired outcome. Several approved drugs have been developed with the aid of CADD. On SciFinder®, we evaluated more than 600 publications through systematic searching and refining, using the terms, virtual screening; software methods; computational studies and publication year, in order to obtain data concerning particular aspects of CADD. The primary focus of this review was on the databases screened, virtual screening and/or molecular docking software program used. Furthermore, we evaluated the studies that subsequently performed molecular dynamics (MD) simulations and we reviewed the software programs applied, the application of density functional theory (DFT) calculations and experimental assays. To represent the latest trends, the most recent data obtained was between 2015 and 2020, consequently the most frequently employed techniques and software programs were recorded. Among these, the ZINC database was the most widely preferred with an average use of 31.2%. Structure-based virtual screening (SBVS) was the most prominently used type of virtual screening and it accounted for an average of 57.6%, with AutoDock being the preferred virtual screening/molecular docking program with 41.8% usage. Following the screening process, 38.5% of the studies performed MD simulations to complement the virtual screening and GROMACS with 39.3% usage, was the popular MD software program. Among the computational techniques, DFT was the least applied whereby it only accounts for 0.02% average use. An average of 36.5% of the studies included reports on experimental evaluations following virtual screening. Ultimately, since the inception and application of CADD in pre-clinical drug discovery, more than 70 approved drugs have been discovered, and this number is steadily increasing over time.
Collapse
Affiliation(s)
- Victor T Sabe
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa.
| | - Thandokuhle Ntombela
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa.
| | - Lindiwe A Jhamba
- HIV Pathogenesis Program, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa
| | - Glenn E M Maguire
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa; School of Chemistry and Physics, University of KwaZulu-Natal, Durban, 4001, South Africa
| | - Thavendran Govender
- Faculty of Science and Agriculture, Department of Chemistry, University of Zululand, KwaDlangezwa, 3886, South Africa
| | - Tricia Naicker
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa
| | - Hendrik G Kruger
- Catalysis and Peptide Research Unit, School of Health Sciences, University of KwaZulu-Natal, Durban, 4001, South Africa.
| |
Collapse
|
9
|
Qiu H, Ali Z, Bender A, Caldwell R, Chen YY, Fang Z, Gardberg A, Glaser N, Goettsche A, Goutopoulos A, Grenningloh R, Hanschke B, Head J, Johnson T, Jones C, Jones R, Kulkarni S, Maurer C, Morandi F, Neagu C, Poetzsch S, Potnick J, Schmidt R, Roe K, Viacava Follis A, Wing C, Zhu X, Sherer B. Discovery of potent and selective reversible Bruton's tyrosine kinase inhibitors. Bioorg Med Chem 2021; 40:116163. [PMID: 33932711 DOI: 10.1016/j.bmc.2021.116163] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2021] [Revised: 04/06/2021] [Accepted: 04/11/2021] [Indexed: 11/29/2022]
Abstract
Bruton's tyrosine kinase (BTK) is a cytoplasmic, non-receptor tyrosine kinase member of the TEC family of tyrosine kinases. Pre-clinical and clinical data have shown that targeting BTK can be used for the treatment for B-cell disorders. Here we disclose the discovery of a novel imidazo[4,5-b]pyridine series of potent, selective reversible BTK inhibitors through a rational design approach. From a starting hit molecule 1, medicinal chemistry optimization led to the development of a lead compound 30, which exhibited 58 nM BTK inhibitory potency in human whole blood and high kinome selectivity. Additionally, the compound demonstrated favorable pharmacokinetics (PK), and showed potent dose-dependent efficacy in a rat CIA model.
Collapse
Affiliation(s)
- Hui Qiu
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1).
| | - Zahid Ali
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Andrew Bender
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Richard Caldwell
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Yi-Ying Chen
- Stoke Therapeutics, 45 Wiggins Ave, Bedford, MA 01730, USA
| | - Zhizhou Fang
- Merck KGaA, Frankfurter Strasse 250, Darmstadt, Hessen, DE 64293, Germany
| | - Anna Gardberg
- Constellation Pharmaceuticals, 215 First St #200, Cambridge, MA 02142, USA
| | - Nina Glaser
- Merck KGaA, Frankfurter Strasse 250, Darmstadt, Hessen, DE 64293, Germany
| | - Anja Goettsche
- Merck KGaA, Frankfurter Strasse 250, Darmstadt, Hessen, DE 64293, Germany
| | - Andreas Goutopoulos
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Roland Grenningloh
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Bettina Hanschke
- Merck KGaA, Frankfurter Strasse 250, Darmstadt, Hessen, DE 64293, Germany
| | - Jared Head
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Theresa Johnson
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Christopher Jones
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Reinaldo Jones
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Shashank Kulkarni
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Christine Maurer
- Merck KGaA, Frankfurter Strasse 250, Darmstadt, Hessen, DE 64293, Germany
| | - Federica Morandi
- Roche Pharma Research and Early Development, Grenzacherstrasse 124, Basel, Basel-Stadt, CH 4070, Switzerland
| | - Constantin Neagu
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Sven Poetzsch
- Merck KGaA, Frankfurter Strasse 250, Darmstadt, Hessen, DE 64293, Germany
| | - Justin Potnick
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Ralf Schmidt
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Katherine Roe
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Ariele Viacava Follis
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Carolyn Wing
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Xiaohua Zhu
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| | - Brian Sherer
- EMD Serono Research & Development Institute, 45A Middlesex Turnpike, Billerica, MA 01821, USA(1)
| |
Collapse
|
10
|
Evaluation of the binding behavior of olmutinib (HM61713) with model transport protein: Insights from spectroscopic and molecular docking studies. J Mol Struct 2021. [DOI: 10.1016/j.molstruc.2020.129024] [Citation(s) in RCA: 57] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
11
|
Zhang J, Gao X, Huang J, Wang H. Probing the Interaction between Human Serum Albumin and 9-Hydroxyphenanthrene: A Spectroscopic and Molecular Docking Study. ACS OMEGA 2020; 5:16833-16840. [PMID: 32685852 PMCID: PMC7364716 DOI: 10.1021/acsomega.0c02031] [Citation(s) in RCA: 38] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/02/2020] [Accepted: 06/22/2020] [Indexed: 05/10/2023]
Abstract
9-Hydroxyphenanthrene (9-OHPhe), the representative hydroxyl metabolite of phenanthrene, has generated increasing concern as it is potentially hazardous to organisms. Herein, multispectroscopic and molecular docking techniques were applied to investigate the molecular interaction of human serum albumin (HSA) with 9-hydroxyphenanthrene (9-OHPhe) under simulated physiological conditions. Steady-state fluorescence and time-resolved fluorescence spectral analysis showed that 9-OHPhe quenched HSA fluorescence through a mixed static and dynamic process. HSA can bind with 9-OHPhe to form a 1:1 complex, with binding constants of 1.28 × 105, 1.36 × 105, and 1.26 × 105 L·mol-1 at 298.15, 303.15, and 308.15 K, respectively. The strong binding between HSA and 9-OHPhe is spontaneous and entropy-driven. Molecular docking indicated that the optimal binding site of 9-OHPhe with HSA was located in the IA subdomain of HSA. Thermodynamic analysis and molecular docking results suggested that hydrophobic interactions and hydrogen bond force dominated the binding process of HSA with 9-OHPhe. Specifically, 9-OHPhe formed hydrophobic interactions with LEU134, LEU139, ILE142, LEU154, PHE157, ALA158, and TYR161 and formed a 1.86 Å hydrogen bond with LEU135. Circular dichroism spectral analysis showed that the α-helical content of HSA decreased from 52.3 to 50.9% after adding 9-OHPhe with a ratio of 1:1. The obtained results are hoped to provide basic data for understanding the potential effects of the hydroxyl metabolites of PAHs on functional biomacromolecules.
Collapse
Affiliation(s)
- Jing Zhang
- . Tel: +86 0596-6289870. Fax:+86 0596-6288214
| | | | | | | |
Collapse
|
12
|
Lyu S, Wang W. Spectroscopic methodologies and computational simulation studies on the characterization of the interaction between human serum albumin and astragalin. J Biomol Struct Dyn 2020; 39:2959-2970. [DOI: 10.1080/07391102.2020.1758213] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- ShaoLi Lyu
- Department of Ecology and Resource Engineering, Hetao College, Bayannur, Inner Mongolia, PR of China
| | - Wang Wang
- Key Laboratory of Bio-resources and Eco-environment of the Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, PR of China
| |
Collapse
|
13
|
Wani TA, Bakheit AH, Zargar S, Rizwana H, Al-Majed AA. Evaluation of competitive binding interaction of neratinib and tamoxifen to serum albumin in multidrug therapy. SPECTROCHIMICA ACTA. PART A, MOLECULAR AND BIOMOLECULAR SPECTROSCOPY 2020; 227:117691. [PMID: 31699587 DOI: 10.1016/j.saa.2019.117691] [Citation(s) in RCA: 24] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/09/2019] [Revised: 10/13/2019] [Accepted: 10/22/2019] [Indexed: 06/10/2023]
Abstract
Co-administration of two drugs to obtain a therapeutic goal is a common practice clinically and for effective use of drug therapy. However, the co-administration can sometimes cause adverse effects due to pharmacokinetic drug interactions. Breast Cancer treatment regimen include tyrosine kinase inhibitor neratinib (NRB) and/or tamoxifen (TMX). In this study neratinib and tamoxifen interaction with bovine serum albumin (BSA) and human serum albumin (HSA) individually and in combination using fluorescence spectroscopy was studied. The aim of this study was to find out whether there is a possibility of either of the two drugs interfering in the plasma protein binding of the other drug. Subdomain IIA of both the BSA and HSA was found to bind tamoxifen and neratinib. The λex = 280 nm and 295 nm were used for the analysis of neratinib-SA, tamoxifen-SA, neratinib: SA in presence of constant concentration of tamoxifen and similarly tamoxifen-SA in presence of constant concentration of neratinib. The interaction study of the binary and the ternary systems suggest that neratinib doesn't affect the interaction between SA and tamoxifen. In contrast, the interaction between neratinib and SA was affected by tamoxifen. The binding constant and quenching constant values suggest that tamoxifen dislodges neratinib from its serum albumin complex whereas neratinib doesn't affect the interaction between SA and tamoxifen. Thus, it was concluded from the results the study that during simultaneous administration of neratinib and tamoxifen, their competition for the SA binding sites should be taken into account.
Collapse
Affiliation(s)
- Tanveer A Wani
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia.
| | - Ahmed H Bakheit
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia; Department of Chemistry, Faculty of Science and Technology, Al-Neelain University, Khartoum, Sudan
| | - Seema Zargar
- Department of Biochemistry, College of Science, King Saud University, PO Box 22452, Riyadh, 11451, Saudi Arabia
| | - Humaira Rizwana
- Department of Microbiology and Botany, College of Science, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia
| | - Abdulrahman A Al-Majed
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh, 11451, Saudi Arabia
| |
Collapse
|
14
|
Zia MK, Siddiqui T, Ali SS, Ahsan H, Khan FH. Deciphering the binding of dutasteride with human alpha-2-macroglobulin: Molecular docking and calorimetric approach. Int J Biol Macromol 2019; 133:1081-1089. [DOI: 10.1016/j.ijbiomac.2019.04.180] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Revised: 04/26/2019] [Accepted: 04/26/2019] [Indexed: 10/26/2022]
|